Onco Actu du 15 mars 2017

	1. Biologie
Mechanism triggers spread of prostate cancer to bones [WSU] Introducing human prostate cancer cell lines into mice, Wu and his colleagues saw a particular enzyme called MAOA activate a cascade of signals that made it easier for tumor cells to invade and grow in bone.
	3.1.1 Tabac - e-cigs
Battery Safety Concerns in Electronic Nicotine Delivery Systems (ENDS) Public Workshop - April 2017 [FDA] Additionally, information related to the communication from tobacco product manufacturers or importers to distributors, wholesalers, retailers, consumers, and the general public on battery-related safety concerns with the use of ENDS products will also be collected.
	4. Dépistage, diagnostic et pronostic
Beyond colour vision – spotting cancer when it hides between the red, green and blue [Cancer Research UK] This is our goal: to use hyperspectral imaging with a combination of colour changes in diseased tissue and application of specific chemical dyes in order to more accurately detect cancers inside the body.
	5. Traitements
Using a ‘kiss of death’ to neutralize disease-causing proteins [FierceBiotech] They call their method the “kiss of death,” and it revolves around modifying small molecules so they draw neutralizing proteins to the bad proteins, which then causes them to degrade, according to a press release.
	5.10 Traitements - Essais
AstraZeneca Takes PARP Inhibitor Fight to Rival Tesaro with Strong Ovarian Cancer Study Results [The Street] AstraZeneca's PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo.
Tesaro shares skid lower as AstraZeneca wows with PhIII data on PARP drug for ovarian cancer [EndPoints] Tesaro has been aiming at a direct showdown with AstraZeneca as it winds up for a likely near-term approval on niraparib. Its reduction in risk compares closely to olaparib, with a PFS rate that won’t look as good.
AstraZeneca ovarian cancer drug slows disease markedly in study [Reuters] Women with recurrent ovarian cancer and defective BRCA genes lived a median 19.1 months without their disease worsening when given Lynparza, against 5.5 months for those on placebo, based on disease progression assessments carried out by investigators.
	5.12 Immunothérapies
Tasmanian Devil Cancer Immunotherapy [The Scientist] Researchers in Australia claim to have successfully used immunotherapy to treat devil facial tumor disease.
	5.12.2 Immunothérapies - CAR-T
Kite Pharma Highlights Publication from the National Cancer Institute Demonstrating Durable Complete Remissions in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Following Low Dose Conditioning Chemotherapy and Anti-CD19 CAR T-Cell Therapy [Kite] In this study, 22 patients with relapsed/refractory NHL received a single dose of anti-CD19 CAR T-cell therapy after a low-dose chemotherapy conditioning regimen consisting of cyclophosphamide and fludarabine.
	5.2.3 Pharma - économie
Top 15 pharma companies by 2016 revenue [FiercePharma] The building tensions over pricing, and a review of the top 15 companies by 2016 revenues, suggests the relentless march forward of drug prices and profits may have slowed.
Pushing ahead with cancer drug research, Peloton brings its latest round to $75M [EndPoints] Much of that money is being earmarked for PT2385, an early-stage drug which Peloton sees as a “first-in-class” small molecule targeting hypoxia inducible factor-2α (HIF-2α), a transcription factor involved in cancer progression. Their lead program is currently in a Phase I study for clear cell renal cell carcinoma, or ccRCC.
	5.3.4 Traitements - AMM (FDA, EMA)
Astex bags milestone after Novartis cancer drug approved [FierceBiotech] Approval of Kisqali comes 11 years after Novartis struck a $520 million (€489 million) deal with Astex to gain the rights to two cell-cycle inhibitors and form a collaboration to discover similar candidates. That led to the publication of a paper on the crystal structure CDK4 by a team mostly made up of people from Astex’s site in Cambridge, U.K.
FDA OKs Merck’s Keytruda for Hodgkin lymphoma, a first in blood cancer [EndPoints] Regulators handed out the OK for patients who had already failed at least three therapies.
Novartis wins U.S. approval for breast cancer drug; to compete with Pfizer's Ibrance [Reuters] The Swiss company has priced Kisqali to be cheaper than Ibrance, which analysts said could help it win business, though Kisqali's approval includes additional patient monitoring requirements that could work against the new drug.
Merck's Keytruda wins FDA nod for treating blood cancer [Reuters] The nod from the FDA marks the first approval of the treatment for blood cancer. Keytruda is already approved for treating lung, head and neck cancers, among others.
	5.5 ASCO
Researchers Find Evidence-Based Radiation Treatment After Lumpectomy Leads to High-Quality, High-Value Care for Patients [ASCO] Researchers accessed the NCDB, a database of clinical and demographic data from tumor registries capturing approximately 70% of all newly diagnosed cancers in the U.S., to identify more than 43,000 women with invasive breast cancers who had received a lumpectomy in 2011.
	6.1 Observation
Survivors of Hodgkin lymphoma over twice as likely to suffer second cancer [Pharmafile] Another aspect to the study found that age was particularly important in the increased risk of a second occurrence of cancer; women who were diagnosed with Hodgkin lymphoma under the age of 35 had 14% risk of developing breast cancer over the next 30 years while those diagnosed over 35 had only a 3% chance.
Hodgkin lymphoma survivors at high risk of second cancers [Institute of Cancer Research] People who survived Hodgkin lymphoma were 2.4 times more likely to develop a second cancer of any type compared with people the same age and sex in the general population – and this risk remained high 30 years after treatment. But the risk was even greater in people who were treated for Hodgkin lymphoma and had a family history of those specific cancers.
	6.11 Patients
Putting the Cancer Patient Front and Center: An Interview with NCI’s Dr. Paul Jacobsen [NCI] My research over the past 3 decades has focused on patient-centered health outcomes, a field that aims to understand the perspectives of patients, family, and caregivers and incorporate those perspectives into health care delivery, with the goal of optimizing patient outcomes.
	6.9 Controverses
How Do We Protect Patients From False Promises In Right-To-Try Laws? [Health Affairs Blog] Everyone with a late-stage terminal illness like my sister deserves the chance to try an experimental therapy. However, serious changes to today’s legislative proposal are needed before this law is safe for patients.